Trial reportAddiction (Abingdon, England)2026
Financial incentives for maintaining postpartum smoking abstinence: 3-4-year follow-up of the Financial Incentives for Prevention of Postpartum Return to Smoking (FIPPS) randomised controlled trial.
Trial report in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
aimsWe followed up a financial incentives trial aimed at maintaining smoking cessation postpartum, which showed some positive effects at one year, to assess sustained abstinence at 3-4 years postpartum. DESIGN, SETTING AND
participantsSecondary analysis of longer-term outcomes of a pragmatic, multi-centre, three-arm randomized controlled trial, recruiting 462 postpartum women in England, aged ≥16 years, having stopped smoking during pregnancy with financial incentives, validated as abstinent at end of pregnancy or early postpartum.
interventions(1) usual care (UC); (2) UC plus up to £60 of voucher incentives offered to participants and £60 offered to significant-other supporters, over 3 months postpartum, contingent upon validated abstinence ('3-months incentives'); or (3) UC plus '3-months incentives' plus £180 of vouchers offered to participants over 9 months postpartum (leading to a maximum of £240 of incentives for participants, plus £60 for significant others), contingent upon validated abstinence ('12-months incentives'). Participants who did not achieve sustained abstinence at one year were included as non-abstainers but were not followed-up. MEASUREMENTS: Primary outcome: biochemically validated abstinence at 3-4 years postpartum. Statistical significance was set at P < 0.017 to account for multiple comparisons.
findingsAmong the full trial sample, 63% (289/462) of participants had self-reported smoking status at 3-4 years postpartum; 19% (88/462) reported as abstinent, of whom 64% (56/88) underwent biochemical validation with none misclassified. Primary outcome abstinence was 16.4% (26/159) for 12-months incentives, 12.3% (19/154) for 3-months incentives and 7.4% (11/149) for UC. Adjusted odds ratios (OR) (95% confidence interval) for 12-months vs. UC: OR 2.51 (1.18-5.31), P = 0.016, and for 3-months vs. UC: 1.81 (0.83-3.98), P = 0.138. In a fully adjusted model, the difference between 12-month incentives and UC was no longer statistically significant: OR 2.44 (1.11-5.36), P = 0.027, using the Bonferroni correction (P < 0.017). Bayes factors indicated that for 12-months vs. UC there was good evidence for the alternative hypothesis and for 3-months vs. UC there was inconclusive evidence for the null or alternative hypothesis.
conclusionsUp to £300 of voucher incentives offered over 12 months postpartum may be effective for maintaining smoking abstinence at 3-4 years postpartum compared with usual care. Up to £120 of incentives over 3 months postpartum does not appear to be beneficial compared with usual care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.